photo walkheader_zpsd5bunpmi.png

Monthly Archives: June 2013

Salivary Biomarkers for Detection of Pancreatic Cancer

A long friend to the mission of our foundation, Al Laporta, DDS of New Your (who lost his beloved mother to pancreatic cancer) reminds us of intriguing work by physician and dentist researchers at UCLA demonstrating proof of concept work published in 2010 in the journal Gastroenterology which identified 12 salivary messenger RNA biomarkers that […]

Oral Thymidylate Synthase Inhibitor as an Alternative to Gemcitabine?

Especially researchers in Japan have been studying the outcomes of the orally administered drug known as S-1 in the treatment of pancreatic cancer (ductal adenocarcinoma of the pancreas).  S-1 is a fluorouracil drug agent (similar to 5FU – fluorouracil), which like 5-FU, functions as an inhibitor of thymidylate synthase.  S-1 is comprised of three components: […]

Overcoming Gemcitabine Resistance – Dasatinib

The drug agent gemcitabine has been the mainstay of the medical treatment of pancreatic cancer (ductal adenocarcinoma of the pancreas).  This assertion has perhaps been challenged by extensive 5-FU combinations in the past couple of years, but is still mostly held to be true by clinicians. The wide adoption of the use of gemcitabine since […]